Fosravuconazole L-lysine ethanolate

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

FosravuconmazeL-赖氨酸乙醇盐是一种广谱抗真菌剂。用于治疗甲癣（一种指甲的真菌感染）。它是一种前药，可转化为雷夫康唑。

FosravuconazoleL-lysine ethanolate is a broad-spectrum antifungal agent. In Japan, it is approved for the treatment of onychomycosis, a fungal infection of the nail. It is a prodrug that is converted into ravuconazole.(In Vitro):Fosravuconazole has potent in vitro antifungal activity against a wide range of fungal species, including Candida, Aspergillus, and Trichophyton species.(In Vivo):Fosravuconazole (E-1224; 10-50 mg/kg; oral administration; daily; for 20 days) treatment suppresses the parasitemia and prevents death in mice infected with the T. cruzi Y strain.

Fosravuconazole has potent in vitro antifungal activity against a wide range of fungal species, including Candida, Aspergillus, and Trichophyton species.

Fosravuconazole (E-1224; 10-50 mg/kg; oral administration; daily; for 20 days) treatment suppresses the parasitemia and prevents death in mice infected with the T. cruzi Y strain. Animal Model:Swiss female mice (20-24 g) inoculated with trypomastigotes (Y strain).Dosage:10 mg/kg, 20 mg/kg, 30 mg/kg, 40 mg/kg, 50 mg/kg Administration:Oral administration; daily; for 20 days Result:Suppressed the parasitemia and prevented death.

BMS-379224 L-lysine ethanolate | E-1224 L-lysine ethanolate

Others

Other Targets

Others

——

——

914361-45-8

739.7

C31H40F2N7O8PS

>98% (HPLC)

DMSO:48mg/mL (64.89mM)

N#CC1=CC=C(C2=CSC([C@H](C)[C@@](OCOP(O)(O)=O)(C3=CC=C(F)C=C3F)CN4N=CN=C4)=N2)C=C1.CCO.N[C@H](C(O)=O)CCCCN

——

(-20℃)

With Ice Pack

≥ 2 years